PTK2 and neoplasm: Despite this, the use of FAK inhibitors in clinical trials has demonstrated modest efficacy in MPM patients in terms of promoting an improved progression-free survival (PFS) and disease stabilisation; only exhibiting an objective response in patients with Merlin-negative tumours [61,62].